With one eye on the future

Carlos Caldas; Maria Rescigno; Samra Turajlic; Anant Madabhushi; Zemin Zhang; Piro Lito; Christine E Brown; Klaus Pantel; John Haanen; Narjust Duma

doi:10.1016/j.ccell.2022.02.019

With one eye on the future

Standard

With one eye on the future. / Caldas, Carlos; Rescigno, Maria; Turajlic, Samra; Madabhushi, Anant; Zhang, Zemin; Lito, Piro; Brown, Christine E; Pantel, Klaus; Haanen, John; Duma, Narjust.

In: CANCER CELL, Vol. 40, No. 3, 14.03.2022, p. 221-225.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Caldas, C, Rescigno, M, Turajlic, S, Madabhushi, A, Zhang, Z, Lito, P, Brown, CE, Pantel, K, Haanen, J & Duma, N 2022, 'With one eye on the future', CANCER CELL, vol. 40, no. 3, pp. 221-225. https://doi.org/10.1016/j.ccell.2022.02.019

APA

Caldas, C., Rescigno, M., Turajlic, S., Madabhushi, A., Zhang, Z., Lito, P., Brown, C. E., Pantel, K., Haanen, J., & Duma, N. (2022). With one eye on the future. CANCER CELL, 40(3), 221-225. https://doi.org/10.1016/j.ccell.2022.02.019

Vancouver

Caldas C, Rescigno M, Turajlic S, Madabhushi A, Zhang Z, Lito P et al. With one eye on the future. CANCER CELL. 2022 Mar 14;40(3):221-225. https://doi.org/10.1016/j.ccell.2022.02.019

Bibtex

@article{c5a3c992f08445d184d19f16ec337028,

title = "With one eye on the future",

abstract = "In the past 20 years we have seen the rise of a new era of cancer research that moved its focus away from the cancer cell itself and revealed a complexity of interactions, both within the tumor and with the host, that ultimately dictate the evolution and progression of the disease. We have witnessed the development of immunotherapies that changed the fate of many patients and new diagnostic strategies with the potential of changing clinical practice. In this article, several experts discuss what lies ahead.",

keywords = "Humans, Immunotherapy, Neoplasms/therapy",

author = "Carlos Caldas and Maria Rescigno and Samra Turajlic and Anant Madabhushi and Zemin Zhang and Piro Lito and Brown, {Christine E} and Klaus Pantel and John Haanen and Narjust Duma",

year = "2022",

month = mar,

day = "14",

doi = "10.1016/j.ccell.2022.02.019",

language = "English",

volume = "40",

pages = "221--225",

journal = "CANCER CELL",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

RIS

TY - JOUR

T1 - With one eye on the future

AU - Caldas, Carlos

AU - Rescigno, Maria

AU - Turajlic, Samra

AU - Madabhushi, Anant

AU - Zhang, Zemin

AU - Lito, Piro

AU - Brown, Christine E

AU - Pantel, Klaus

AU - Haanen, John

AU - Duma, Narjust

PY - 2022/3/14

Y1 - 2022/3/14

N2 - In the past 20 years we have seen the rise of a new era of cancer research that moved its focus away from the cancer cell itself and revealed a complexity of interactions, both within the tumor and with the host, that ultimately dictate the evolution and progression of the disease. We have witnessed the development of immunotherapies that changed the fate of many patients and new diagnostic strategies with the potential of changing clinical practice. In this article, several experts discuss what lies ahead.

AB - In the past 20 years we have seen the rise of a new era of cancer research that moved its focus away from the cancer cell itself and revealed a complexity of interactions, both within the tumor and with the host, that ultimately dictate the evolution and progression of the disease. We have witnessed the development of immunotherapies that changed the fate of many patients and new diagnostic strategies with the potential of changing clinical practice. In this article, several experts discuss what lies ahead.

KW - Humans

KW - Immunotherapy

KW - Neoplasms/therapy

U2 - 10.1016/j.ccell.2022.02.019

DO - 10.1016/j.ccell.2022.02.019

M3 - Other (editorial matter etc.)

C2 - 35290781

VL - 40

SP - 221

EP - 225

JO - CANCER CELL

JF - CANCER CELL

SN - 1535-6108

IS - 3

ER -